Hep C Experts Condemn Cochrane Review Dissing Direct Antivirals

Earlier this month, a pooled analysis by the prestigious Cochrane Collaboration questioned whether sofosbuvir and other direct-acting antivirals (DAAs) can actually save lives in the long run -- a finding that could deal a massive blow to hepatitis C patients and drug companies alike. The problem is that it's simply not true, according to a chorus of experts who have called the Cochrane review "outdated," "fundamentally flawed," and "absurd." In an

The Week in Review: June 2 – June 9, 2017

Friday, June 9, 2017 News Recap Somebody Pinch Me This week saw the release of a report from the Cochrane Collaboration which concluded not only that DAAs were ineffective but that they might also be bad for you and not even cure HCV.  The news item was picked up by various media outlets and was hard to miss (No valid evidence $40,000 miracle drug cures hepatitis C – study).  Thankfully other researchers from around the world jumped in on this poor ...

The Hepatitis C Trust responds to study on hepatitis C treatment

In recent days there has been media coverage of a new study that casts doubt upon the effectiveness of new hepatitis C treatments. Given the potential that the coverage of this study has to mislead patients, The Hepatitis C Trust wishes to make clear that we have fundamental doubts as to the credibility of the research. Along with leading clinicians and scientists, we have written to The Guardian to express our concern. The letter states: We are clinician